Indications and outcomes of transjugular intrahepatic portosystemic shunt insertion in two regional Australian hepatology centres
Internal Medicine Journal · 2024
DOI: 10.1111/imj.16384 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Natalie Commins und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Sunshine Coast University Hospital, Sunshine Coast, Queensland, Australia. Hauptthemen laut MEDLINE: Hypertension, Portal, Portasystemic Shunt, Transjugular Intrahepatic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Transjugular intrahepatic portosystemic shunt (TIPS) is an important therapy for complications of portal hypertension but remains underutilised in regional settings.
Aims
The aim of this study is to explore the demographics, indications, outcomes and complications in patients undergoing TIPS in two regional hepatology centres.
Methods
Retrospective analysis was undertaken of all patients undergoing TIPS at two regional centres between January 2017 and March 2023. The primary outcome measures were efficacy and complications of TIPS. Patient demographics (such as age, baseline liver severity scores and aetiology of liver disease) and indications for TIPS are detailed.
Results
Forty‐eight patients underwent TIPS. Median age was 56 years (interquartile range (IQR): 46–65). The most common indications for TIPS were refractory ascites ( n = 17) and failure of secondary prophylaxis of variceal bleeding ( n = 13). Cumulative survival at 3 months and 1 year was 93% and 77% respectively. There was no significant difference in outcomes based on TIPS indication. The median number of paracenteses in patients undergoing TIPS for refractory ascites 1 year pre‐ and post‐TIPS were 10 (IQR: 4.5–16) and 2 (IQR: 0–4) respectively ( P < 0.001). There were no procedure‐related deaths. Inpatient management of liver disease complications had a mean cost of $32 874.67 (SEM: 7779) in 1 year pre‐TIPS compared with $12 304.70 (SEM: 3531.1) in 1 year post‐TIPS ( P < 0.001).
Conclusions
TIPS is a safe and effective treatment to reduce complications of portal hypertension and can be performed successfully in the regional setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatology, Sunshine Coast University Hospital, Sunshine Coast, Queensland, Australia.
- Department of Hepatology, Gold Coast University Hospital, Southport, Queensland, Australia.
- Department of Interventional Radiology, Sunshine Coast University Hospital, Sunshine Coast, Queensland, Australia.
- University of the Sunshine Coast, Sunshine Coast, Queensland, Australia.
ORCID-Profile: Natalie Commins, James O'Beirne
Zitieren
APA
Commins, N., Subhaharan, D., Kurup, R., Wickremeratne, T., Mitchell, J., Elmes, J., Braund, A., Funakoshi, N., Langton, J., Leschke, P., & O'Beirne, J. (2024). Indications and outcomes of transjugular intrahepatic portosystemic shunt insertion in two regional Australian hepatology centres. Internal Medicine Journal. https://doi.org/10.1111/imj.16384
Vancouver
Commins N, Subhaharan D, Kurup R, Wickremeratne T, Mitchell J, Elmes J, et al. Indications and outcomes of transjugular intrahepatic portosystemic shunt insertion in two regional Australian hepatology centres. Internal Medicine Journal. 2024. doi:10.1111/imj.16384
BibTeX
@article{Commins2024,
author = {Commins, Natalie and Subhaharan, Deloshaan and Kurup, Rajiv and Wickremeratne, Tehara and Mitchell, Jonathan and Elmes, Julie and Braund, Alicia and Funakoshi, Natalie and Langton, Jonathan and Leschke, Paul and O'Beirne, James},
title = {Indications and outcomes of transjugular intrahepatic portosystemic shunt insertion in two regional Australian hepatology centres},
journal = {Internal Medicine Journal},
year = {2024},
doi = {10.1111/imj.16384}
}
EUVIMED